NEWS AND PRESS

The study by the University Hospital Bonn examines the impact of AI tools on the quality of findings in aneurysm detection using MRI images. For the study, the mdbrain Aneurysm Module was used for automatic detection of intracranial aneurysms in TOF sequences.

Active Surveillance is increasingly establishing itself as a pioneering treatment for prostate cancer. We met with Prof. Dr. Michaely from the MVZ Karlsruhe for a discussion on this topic. In this brief interview, he answers questions regarding the significance of AI for further establishment, as well as the potential influence of contrast agents on the implementation of Active Surveillance.

With the update of mdprostate 1.3, the first fully automatic tool for identification and classification of lesions according to PI-RADS 2.1 with longitudinal evaluation is now available. Additionally, the performance of the tool has been significantly improved.

With the latest version of mdbrain (4.11), in addition to the automatic differentiation of the tumor core and surrounding T2/FLAIR hyperintensities of glioblastomas, metastases and meningiomas are now also segmented.

In January 2023, the approval of Lecanemab sparked excitement among neurologists and radiologists, a historic breakthrough as the first promising Alzheimer's treatment. With this effective pharmaceutical option, MRI-based brain diagnostic procedures gain tremendous importance for early detection of neurodegenerative diseases.

As we bid farewell to an outstanding 2023, mediaire stands triumphant, experiencing exceptional growth in our customer base and product usage.

The bender Group, 100% owner of medigration GmbH, an established RIS/PACS company, is collaborating with mediaire on the development of AI image recognition software for Ferrotran®. The MRI contrast agent by SPL Medical BV, with the bender group as majority stakeholder, is currently in the final phase of clinical approval studies. With the creation of mdprostate, mediaire brings extensive experience in the development of AI image recognition software for prostate cancer to the partnership.

With great enthusiasm, we would like to share a pivotal milestone in our company's history with you today. Our latest product, mdprostate, has obtained approval for the European market (CE Certificate) and is registered as a Class IIb medical device. This significant achievement solidifies our commitment to cutting-edge technologies in radiology.

With mdbrain version 4.8, the module Aneurysm Detection has been improved significantly. In this process, the positive and constructive feedback from our users has directly contributed to the product's further development, helping our aim to provide even more targeted support to radiologists.

This topic has been discussed intensively and also controversially in the german radiology community for quite some time now. Is it legitimate to offer elective services for patients, and if so, which ones and in which context?